A Phase Ib/II Clinical Trial to Evaluate the Anti-tumor Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Anti-PD-1/L1 Antibody and Chemotherapy as First-line Treatment in Extensive-stage Small Cell Lung Cancer

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).

Start Date30 Oct 2023

Sponsor / Collaborator

Inxmed (Shanghai) Co., Ltd

NCT05982522 / Not yet recruitingPhase 1/2

A Multicenter, Open-Label, Randomized, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Taxane and Anti-PD-1/L1 Monoclonal Antibody in Previously-treated Solid Tumors

This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal antibody in patients with locally advanced or metastatic solid tumors who have failed in or been intolerant to at least one line of standard therapy. This study will be firstly carried out in previously-treated non-small cell lung cancer (NSCLC) population,

Start Date01 Aug 2023

Sponsor / Collaborator

Inxmed (Shanghai) Co., Ltd

NCT05994131 / RecruitingPhase 1/2

A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Start Date13 Jul 2023

Sponsor / Collaborator

Inxmed (Shanghai) Co., Ltd

100 Clinical Results associated with Ifebemtinib

100 Translational Medicine associated with Ifebemtinib

100 Patents (Medical) associated with Ifebemtinib

Literatures (Medical) associated with Ifebemtinib

01 Dec 2021·Discover. Oncology

Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer

Article

Author: Li, Hong ; Ren, Chenchen ; Gao, Yizhi

Abstract:

Focal adhesion kinase (FAK) activation has been reported to be associated with cell progression and metastasis in a wide variety of cancer cells. Target treatment by inhibiting FAK has achieved remarkable effects in several cancers, but the effect in ovarian cancer has not been reported. In this study, we determined the role and the underlying molecular mechanism of BI853520, a novel small chemical FAK inhibitor against ovarian cancer. Results show that phosphorylated FAK tyrosine 397 (p-FAK Y397) is highly expressed in ovarian cancer tumor tissues and cell lines (SKOV3 and OVCAR3). BI853520 treatment greatly suppresses cell proliferation, viability, migration, invasion, decreases anchorage-independent growth and motility in vitro. Besides, treatment with BI853520 increases biologic effects following combination with chemotherapy in ovarian cancer cell lines. In addition, BI853520 suppresses EMT in ovarian cancer cell lines. Mechanically, BI853520 treatment downregulates the activation of PI3K/AKT/mTOR signal pathway. Finally, mice model experiments confirm BI853520 treatment dramatically reduces tumor growth in vivo and suppresses the activation of PI3K/AKT/mTOR signal pathway. Taken together, our findings demonstrate that focal adhesion kinase inhibitor BI853520 inhibits cell proliferation, migration, invasion and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer, and BI853520 can offer a preclinical rationale for targeting repression of FAK in ovarian cancer.

01 Aug 2021·Advanced science (Weinheim, Baden-Wurttemberg, Germany)Q1 · MATERIALS SCIENCE

Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

Q1 · MATERIALS SCIENCE

ArticleOA

Author: Jiao, Bo ; Zhang, Baoyuan ; Wang, Zaiqi ; Liu, Ping ; Ren, Ruibao ; Zhang, Yan ; Zhang, Jiangwei

Abstract:

KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major concern. Here, it is demonstrated that KRAS G12C inhibition induces sustained activation of focal adhesive kinase (FAK) and show that a combination therapy comprising KRAS G12C inhibition and a FAK inhibitor (IN10018) achieves synergistic anticancer effects. It can simultaneously reduce the extent of drug resistance. Diverse CDX and PDX models of KRAS G12C mutant cancer are examined and synergistic benefits from the combination therapy are consistently observed. Mechanistically, it is found that both aberrant FAK–YAP signaling and FAK‐related fibrogenesis impact on the development of KRAS G12C inhibitor resistance. This study thus illustrates the mechanism of resistance of cancer to the treatment of KRAS G12C inhibitor, as well as an innovative combination therapy to improve treatment outcomes for KRAS G12C mutant cancers.

01 Jan 2021·Cancer biology & medicineQ2 · MEDICINE

Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells

Q2 · MEDICINE

ArticleOA

Author: Rashid, Rufiaat ; Wang, Zaiqi ; Xu, Yao ; Ding, Ding ; Liberto, Juliane ; Li, Keyu ; Wang, Jianxin ; Niu, Nan ; Wolfgang, Christopher L ; Blair, Alex B ; Laheru, Daniel ; Zheng, Lei ; Osipov, Arsen ; Liu, Yanan ; Li, Shiqi ; Burkhart, Richard A ; Herbst, Brian

Objective:

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote an immunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhance effector T cell infiltration. FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies. Thus, we investigated the impact of FAK inhibition on RT, its potential as an RT sensitizer and immunomodulator in a murine model of PDAC.

Methods:

We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT.

Results:

In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT. Antitumor activity of the combination of FAKi and RT is T cell dependent. FAKi in combination with RT enhanced CD8+ T cell infiltration significantly in comparison to the radiation or FAKi treatment alone (P < 0.05). FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone (P < 0.01).

Conclusions:

These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy.

News (Medical) associated with Ifebemtinib

30 May 2024

·www.prnewswire.com

InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Ifebemtinib in combination with garsorasib in NSCLC showed ORR of 90.3% and DCR of 96.8% Ifebemtinib is a highly selective, orally administered, focal adhesion kinase inhibitor with significant synergies with a broad spectrum of therapeutic modalities NANJING, China, May 30, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, today announced results from the Phase Ib/II clinical trial of ifebemtinib, the company's focal adhesion kinase (FAK) inhibitor, in combination with garsorasib, a specific inhibitor of the KRAS G12C mutation, for the first-line treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation. These results will be featured in a poster presentation (Abstract: 8605 | Poster #469) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024, in Chicago, IL. As of the cutoff date of May 10, 2024, a total of 33 subjects were enrolled in the study. Among the 31 evaluable patients, the antitumor responses were assessed and summarized as follows: The objective response rate (ORR) was 90.3% (95% CI: 74.3, 98.0), and the disease control rate (DCR) was 96.8% (95% CI: 83.3, 99.9). A total of 28 partial responses (PRs) and two stable diseases (SDs) were reported. Twenty-six out of 28 PRs were confirmed thus far. The data for median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) are still maturing. The overall safety profile of the combination of ifebemtinib with garsorasib is consistent with either ifebemtinib or garsorasib monotherapy. Most treatment-related adverse events (AEs) were Grade 1 or 2, and some Grade 3 AEs were reported. "The objective responses in patients exceeded our initial expectations. The combination regimen was well tolerated with known, non-overlapping, and manageable AEs from both agents," said Zhengbo Song, M.D., Associate Professor, Director of Phase 1 Unit, Zhejiang Cancer Hospital, University Chinese Academy of Sciences and Principal Study Investigator. "These data warrant further investigation to assess the potential of ifebemtinib to impact the future standard of care for KRAS G12C mutant-driven NSCLC, with or without immunotherapies in the combination regimen." "We are highly encouraged by the results of the current clinical study of ifebemtinib in NSCLC. RAS mutations account for approximately 30 percent of all cancer patients, and KRAS mutations, including the G12C mutation, wreak havoc in many people with solid tumors, including lung, pancreatic, and colorectal cancers," stated James McLeod, M.D., Chief Medical Officer of InxMed. "With recent rapid advances in KRAS G12C inhibitors comes the need for further improving clinical responses and safety/tolerability profiles of treatment regimens. We have studied FAK tumor biology and designed the combination therapy with KRAS inhibitors based on our deep understanding of FAK's roles in the tumor defense mechanism. We are pleased to see that ifebemtinib significantly amplifies the clinical responses of the combination regimen." Dr. McLeod added, "The current data set, albeit early with PFS and DOR data, is still maturing but is consistent with the results from our clinical trials in other tumor types. These initial findings demonstrate the potential of ifebemtinib to become an anchor component in combination regimens with chemotherapies, targeted therapies, or immunotherapies. We will continue further exploring the clinical utility of ifebemtinib in combination therapy and certainly welcome collaborations with global leaders in cancer therapies." About Ifebemtinib Ifebemtinib (IN10018, BI853520) is a highly selective, orally administered, small molecule inhibitor for focal adhesion kinase, which has significant synergies with a broad spectrum of therapeutic modalities. Clinically, ifebemtinib has demonstrated therapeutic synergies with chemotherapy agents, targeted therapies, and immunotherapies. InxMed is currently pursuing a registrational trial in platinum-resistant ovarian cancer in China, and multiple proof-of-concept trials are ongoing in lung, colorectal, melanoma, and pancreatic cancers, with select tumor types to progress into pivotal clinical trials. Thus far, more than 600 patients have been treated with ifebemtinib, and a favorable safety and tolerability profile was observed. Ifebemtinib was granted Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) and Fast-Track designation from the U.S. Food and Drug Administration (FDA). InxMed plans to submit a New Drug Application to the NMPA in early 2025. About InxMed InxMed Co. Ltd is a clinical-stage biotech company developing innovative therapies against tumor treatment resistance and metastasis. Established in 2018, InxMed has built an efficient engine for clinical translational research driven by an in-depth understanding of disease biology. InxMed's pipeline includes several compounds targeting tumor defense mechanisms with highly differentiated therapeutic candidates. For more information, visit en.inxmed.com. SOURCE InxMed Ltd

Clinical ResultFast TrackASCOImmunotherapyPhase 1

20 Dec 2023

·www.prnewswire.com

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs. The license agreement provides InxMed with right to use EZWi-Fit® platform on the several novel ADC candidate molecules. InxMed will have the right for development, manufacturing, and commercialization of these ADC candidate molecules. InxMed is developing next generation TAAs targeting ADCs with significant improvement of efficacy and therapeutic window. Meanwhile, the company is developing solutions to boost ADC's efficacy including enhancing ADC penetration via FAK inhibitor and developing stroma targeting ADC to create synergy. InxMed is positioned to invent next generation ADCs, with the attributes to be more tumor selective and potent, and broad combination potential. The novel antibodies discovered by InxMed to be equipped with payload from EZWi-Fit®platform will be one of key differentiations. About InxMed InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies against tumor resistance and metastasis. InxMed is committed to build an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology. InxMed has translational medicine and clinical teams at Nanjing，Shanghai and Beijing in China, and has team members located in the United States, Canada and Australia. Through its own discovery research and development, and collaborative research and development, InxMed has built a highly differentiated, and intrinsic synergistic pipeline. InxMed has completed several rounds of financing totaling more than 100 million US dollars raised. Its first developing drug, IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), received Fast-track Designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation from the China National Medical Products Administration against platin resistant ovarian cancer. The pivotal clinical trial is ongoing. About EZWi-Fit ® EZWi-Fit® is the State-of-the-Art ADC platform technology invented by Escugen with the global IP rights. It couples a potent Topoisomerase I inhibitor with high and homogeneous drug-antibody ratio (DAR) to the antibody with a stable cleavable linker. The proprietary chemical modification of the linker not only confers the conjugates with excellent hydrophilicity, but also minimizes the de-conjugation of the linker-payload. Outstanding Pharmacokinetic features so derived provides ADC with substantial in vivo efficacy, which is superior to that of GGFG-Dxd ADC in multiple CDX and PDX models, involving different targets and antibodies. Great By-stander Effect of the linker-payload warrants specific and significant efficacy in various low affluence and high heterogenicity target expressing tumor models, which is even resistance to MMAE and Dxd ADC. The EZWi-Fit® derived ADC is well tolerated in the Non-Human Primate toxicology studies, without reaching the Maximum Tolerable Dose (MTD) at 60-80 mg/kg. With this edge-cutting technology, Escugen is quickly expanding the Frist-in-Class ADC pipeline to satisfy the unmet medical needs. About Escugen Escugen was founded in 2017，focusing on the development of innovative Antibody Drug Conjugates (ADC) for cancer therapy. The founders of Escugen are veterans of biotech industry, with rich working experience gained in the leading companies of both China and the US. The expertise of its research team covers antibody discovery, bio-conjugation, process development, quality research, preclinical and clinical studies. The most advanced project, ESG401, currently in PhIb/II clinical trials, is a TROP-2 ADC that uses an innovative stable cleavable linker designed for significant reduction of the off-target toxicity. Topoisomerase I inhibitor is the payload, with the Drug-Antibody Ratio (DAR) at 8 homogeneously. Clinical data shows that the tolerable dose of ESG401 is remarkably greater than that of other ADCs to the same target. The incidence of the Off-target toxicity, such as neutropenia, is low and mild, and no diarrhea greater than Grade 3 has been reported. The On-target Off-tumor toxicity, such as stomatitis, was rare. In the patients with heavily treated metastatic triple-negative and HR+/Her-2- breast cancer, promising evidence of efficacy has been observed, including the regression of the visceral and intracranial metastatic lesions. SOURCE InxMed Co., Ltd

License out/inFast TrackADC

23 Oct 2023

·www.prnewswire.com

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in platinum-resistant recurrent ovarian cancer (PROC) and triple-negative breast cancer (TNBC) has been presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid, Spain. Both of the two studies showed that patients receiving IN10018 containing regimens demonstrated promising antitumor activities with trends toward survival benefit. Platinum-Resistant Recurrent Ovarian Cancer（Poster #：753P） In a single-arm, open-label, phase Ib trial, PROC patients received IN10018 in combination with pegylated liposomal doxorubicin (PLD) treatment. The combination of IN10018 with PLD showed prolonged survival in PROC patients and manageable safety profile. As of cutoff date of April 28, 2023, a total of 61 patients were enrolled with median follow-up duration of 14.0 months. Comparing with historical data by PLD alone with an ORR (Objective Response Rate) of ~10%, median PFS (Progression-Free Survival) of 3.3 months and median OS (Overall Survival) of 12 months, the ORR of PLD in combination with IN10018 was 46.3% (95% CI：32.6-60.4), the DCR (Disease Control Rate) was 83.3% (95% CI 70.7-92.1), the median PFS was 7.56 months (95% CI: 5.5 – 9.1 months), the median OS was 20.9 months (95% CI: 14.4 months – NA) and still maturing. The safety profile of the combination is comparable to these single agents alone without additive toxicities. Triple-Negative Breast Cancer (Poster#：398P) This phase Ib/II study was to evaluate the safety, tolerability, and antitumor activity of IN10018 combined with PLD with/without anti-PD-1 antibody Toripalimab in previously-treated solid tumors with metastatic TNBC who had failed in 1-2 lines of systemic therapy. As of the cutoff date of August 31, 2023, 12 patients received IN10018 + PLD (doublet) and 14 patients received IN10018 + PLD + Toripalimab (triplet). Historical data showed a median PFS was 4.3 months when PLD and low dose of cyclophosphamide is combined with anti-PD-1. In doublet group, the median PFS was 3.65 months (95% CI：1.77-7.29), and median OS was 8.26 months (95% CI, 5.59-NA). In triplet group, the median PFS was 7.43 months (95% CI：3.02-10.8), and median OS was not reached with the low boundary of 95% CI as 9.26 months. The safety profiles of both doublet group and triplet group in metastatic TNBC are tolerable and comparable to each single agent alone. FAK signaling has been shown to be critical in pathologic fibrosis and is hyperactivated in many cancer types. FAK activation is correlated with poor survival and treatment resistance of tumors. InxMed is developing IN10018 globally. IN10018 has received fast track designation from the U.S. Food and Drug Administration (FDA) and breakthrough designation from China National Medical Products Administration (NMPA). A placebo-controlled, randomized, double-blind Phase II pivotal trial is ongoing to confirm the observed efficacy and safety of IN10018 in PROC. New Drug Application (NDA) is expected to be submitted in 2024. About InxMed InxMed is a clinical-stage biotech company established in 2018. The company dedicates on developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed commits to develop revolutionary cancer therapies. InxMed has teams located in Nanjing, Shanghai and Beijing in China, and hubs in the United States, Canada and Australia. Through its own discovery research and development, and collaborative research and development, InxMed has built an unique innovative pipeline. The company has completed several rounds of financing totaling more than 100 million US dollars. SOURCE InxMed Co., Ltd

Clinical ResultFast TrackPhase 1Phase 2

100 Deals associated with Ifebemtinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Cancer	Phase 3	CN	Inxmed (Shanghai) Co., Ltd	29 Aug 2022
Ovarian Cancer	Phase 3	HK	Inxmed (Shanghai) Co., Ltd	29 Aug 2022
ES-SCLC	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	20 Sep 2023
EGFR positive non-small cell lung cancer	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	13 Jul 2023
Advanced Pancreatic Adenocarcinoma	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	08 Dec 2022
KRAS G12C mutation Solid Tumors	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	12 Oct 2022
Locally Advanced Malignant Solid Neoplasm	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	10 Mar 2022
Solid tumor	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	10 Mar 2022
Ovarian Serous Adenocarcinoma	Phase 2	CN	Inxmed (Shanghai) Co., Ltd	27 Jul 2020
Pancreatic Cancer	Phase 1	CN	Inxmed (Shanghai) Co., Ltd	01 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06166836 \| NCT05379946 (ESMO2024) Manual	Phase 1/2	KRAS G12C mutation Solid Tumors Second line \| First line KRAS G12C	48	Ifebemtinib (100mg qd) + D-1553 (600mg bid) (KRAS G12C mutant NSCLC)	qpncqqkoxn(hamxtvapuq) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. hvknzfjppm (anotfjcjos ) View more	Positive	14 Sep 2024
				Ifebemtinib (100mg qd) + D-1553 (600mg bid) (KRAS G12C mutant metastatic CRC)
NEWS Manual	Phase 1/2	KRAS G12C mutant Non-small Cell Lung Cancer First line KRAS G12C	33	ifebemtinib+garsorasib	csitgrqsre(perwjjalvc) = bsdsenyycm yryhzdvfgm (lvoeqetzeg ) View more	Positive	03 Jun 2024
NCT06166836 \| NCT05379946 (ASCO2024)	Phase 1/2	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C mutation	33	Ifebemtinib (IN10018) 100mg qd	cvapnnbgfl(lngttsgkyp) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. Six subjects (18.1%) had ≥ Grade 3 ifebemtinib-related AEs as assessed by investigators, and all were also D-1553 related AEs. The majority of ifebemtinib-related AEs were CTCAE Grade 1 or 2. There was no event leading to study treatment discontinuation. gjclxptuax (iwlzclojxg ) View more	Positive	24 May 2024
				D-1553 (garsorasib) 600mg bid
IN10018-010 (ESMO2023)	Phase 1/2	Triple Negative Breast Cancer	26	IN10018+PLD	cqaiklrdut(jrmxqjkdtg) = zikuevxarm htpctmfdpu (torrxfqfze, 2.1 - 48.4) View more	Positive	21 Oct 2023
				IN10018+PLD+Toripalimab	cqaiklrdut(jrmxqjkdtg) = ubozjzhfea htpctmfdpu (torrxfqfze, 3.8 - 42.8) View more
NCT05551507 (NEWS) Manual	Phase 1	Ovarian Cancer	50	liposomal doxorubicin+IN10018	xfwhgjgdue(cdxlsvomqu) = uxmlcqohdz isdkotnvjt (ntcrdtuzwu ) View more	Positive	11 Nov 2022
CSCO2022	Phase 1	Platinum-Resistant Ovarian Carcinoma	50	IN10018 100mg QD + PLD 40mg/m2 Q4W	ceejmokbzv(jupmwwbuhv) = olartdimmt wlqwgerlex (fexvycrsjt, 38.7%, 70.2%) View more	Positive	21 Sep 2022
ASCO2022 Manual	Phase 1	Platinum-Resistant Ovarian Carcinoma	42	Pegylated liposomal doxorubicin+IN10018	byfzupdzda(laewsvbnpm) = khccgdvlhi wvltsshvcn (defdwcyqte, 37.4 - 74.5) View more	Positive	02 Jun 2022
				Pegylated liposomal doxorubicin+IN10018 (patients who had at least 6 months of follow up)	byfzupdzda(laewsvbnpm) = fuexsdzpge wvltsshvcn (defdwcyqte, 40.8 - 84.6) View more
NCT01335269 (Pubmed \| Target Oncol) Manual	Phase 1	Neoplasms	96	BI 853520 (200 mg QD)	ocwnaujcbm(xtfbofkplr) = rosqiuujve ypjflizgfn (tcforosghz ) View more	Positive	01 Feb 2019
				BI 853520	cvyjoxgliz(zkzhzmacru) = osqisothcp lxoxbcdcif (udeocpgkpl ) View more
NCT01905111 (Pubmed \| Target Oncol) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	21	BI 853520	rblfottcuj(jxgvqlrnxi) = mjpnknouqv kybewogdfn (qkxflweopx ) View more	Positive	01 Feb 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ifebemtinib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation